ArticleFrontiers in public health2024
Sustainable performance evaluation of pharmaceutical companies: sustainable balanced scorecard and hybrid MCDM approach.
Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the increasing demand for sustainable development of pharmaceutical companies due to the rigorous pressure of environmental regulation, public health crisis and economic competition, there has been little research on relevant evaluation models. The COVID-19 experience has also prompted investors in pharmaceutical companies to re-examine the impact of environment and ethics on business development. Therefore, pharmaceutical companies need to focus on their performance, especially on the shift from a single financial performance to an integrated performance. This paper constructs a reticulated sustainable performance evaluation model for decision-makers based on the Sustainability Balanced Scorecard (SBSC) framework. The evaluation results are derived using Decision Making Experiment and Evaluation Laboratory (DEMATEL), Analytical Network Process (ANP) and modified VlseKriterijumska Optimizacija I Kompromisno Resenje (VIKOR). The model can help management gain a more comprehensive understanding of the company's overall situation, promote management's focus on the balance and synergies between the various dimensions and indicators of sustainability performance, clarify the relationships and the comment weights of evaluation dimensions and indicators, and provide sustainability improvement solutions, which have been neglected in previous research on the evaluation of sustainability performance of pharmaceutical companies. Based on questionnaires with experts, this paper finds that the Environment is the most important factor, followed by Internal Processes, Customers, Finance, Learning and Growth, as well as Society. The empirical results of a Chinese pharmaceutical company suggest that green transformation and customer relations are the priorities, in addition to the need for additional ways to improve the sustainability performance of pharmaceutical companies. The evaluation results provide a strategic reference for stakeholders, which helps the case company to find better strategies for sustainable development and priorities for improving their sustainability performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.